2 neuropathologies

1

3

8

21

- 4 Davis C. Woodworth, PhD^{1,2}, Nasim Sheikh-Bahaei, MD, PhD³, Kiana A. Scambray, BA^{1,2},
- 5 Michael J. Phelan, PhD², Mari Perez-Rosendahl, MD^{1,4}, María M. Corrada, ScD^{1,2,5}, Claudia H.
- 6 Kawas, MD^{1,2,6}, S. Ahmad Sajjadi, MD, PhD^{1,2}, for the Alzheimer's Disease Neuroimaging
- 7 Initiative*
- 9 ¹Department of Neurology, University of California, Irvine, CA, USA
- ²Institute for Memory Impairments and Neurological Disorders, University of California, Irvine,
- 11 CA, USA
- ³Department of Radiology, University of Southern California, Los Angeles, CA, USA
- ⁴Department of Pathology and Laboratory Medicine, University of California, Irvine, CA, USA
- ⁵Department of Epidemiology, University of California, Irvine, CA, USA
- 15 ⁶Department of Neurobiology and Behavior, University of California, Irvine, CA, USA
- *Data used in preparation of this article were obtained from the Alzheimer's Disease Neuroimaging
- 17 Initiative (ADNI) database (adni.loni.usc.edu). As such, the investigators within the ADNI
- 18 contributed to the design and implementation of ADNI and/or provided data but did not participate
- in analysis or writing of this report. A complete listing of ADNI investigators can be found at:
- 20 http://adni.loni.usc.edu/wp-content/uploads/how to apply/ADNI Acknowledgement List.pdf
- 22 Corresponding Author:
- 23 S. Ahmad Sajjadi, MD, PhD
- Office 364, Med Surge II, Academy way, Irvine, California, 92697, USA
- 25 ssajjadi@uci.edu
- 26 Research Support:
- 27 R01AG062706
- 28 R01AG021055
- 29 Disclosures:
- 30 Dr. Davis C. Woodworth reports no disclosures
- 31 Dr. Nasim Sheikh-Bahaei reports no disclosures

- 2 Dr. Michael J. Phelan reports no disclosures
- 3 Dr. Mari Perez-Rosendahl reports no disclosures
- 4 Dr. Claudia H. Kawas reports no disclosures
- 5 Dr. Maria M. Corrada reports no disclosures
- 6 Dr. S. Ahmad Sajjadi reports no disclosures
- 7 Type of Manuscript:
- 8 Original Research
- 9 <u>Running Title</u>:
- 10 Dementia and atrophy of medial temporal lobe independent of pathologies
- 11 Key Words:
- 12 Dementia, MRI, medial temporal lobe, atrophy, neuropathology
- 13 Acknowledgments:
- 14 The NACC database is funded by NIA/NIH Grant U01 AG016976. NACC data are contributed
- by the NIA-funded ADCs: P30 AG019610 (PI Eric Reiman, MD), P30 AG013846 (PI Neil
- 16 Kowall, MD), P30 AG062428-01 (PI James Leverenz, MD) P50 AG008702 (PI Scott Small, MD),
- 17 P50 AG025688 (PI Allan Levey, MD, PhD), P50 AG047266 (PI Todd Golde, MD, PhD), P30
- 18 AG010133 (PI Andrew Saykin, PsyD), P50 AG005146 (PI Marilyn Albert, PhD), P30 AG062421-
- 19 01 (PI Bradley Hyman, MD, PhD), P30 AG062422-01 (PI Ronald Petersen, MD, PhD), P50
- 20 AG005138 (PI Mary Sano, PhD), P30 AG008051 (PI Thomas Wisniewski, MD), P30 AG013854
- 21 (PI Robert Vassar, PhD), P30 AG008017 (PI Jeffrey Kaye, MD), P30 AG010161 (PI David
- Bennett, MD), P50 AG047366 (PI Victor Henderson, MD, MS), P30 AG010129 (PI Charles
- DeCarli, MD), P50 AG016573 (PI Frank LaFerla, PhD), P30 AG062429-01(PI James Brewer,
- 24 MD, PhD), P50 AG023501 (PI Bruce Miller, MD), P30 AG035982 (PI Russell Swerdlow, MD),
- 25 P30 AG028383 (PI Linda Van Eldik, PhD), P30 AG053760 (PI Henry Paulson, MD, PhD), P30
- 26 AG010124 (PI John Trojanowski, MD, PhD), P50 AG005133 (PI Oscar Lopez, MD), P50
- 27 AG005142 (PI Helena Chui, MD), P30 AG012300 (PI Roger Rosenberg, MD), P30 AG049638
- 28 (PI Suzanne Craft, PhD), P50 AG005136 (PI Thomas Grabowski, MD), P30 AG062715-01 (PI
- 29 Sanjay Asthana, MD, FRCP), P50 AG005681 (PI John Morris, MD), P50 AG047270 (PI Stephen
- 30 Strittmatter, MD, PhD).

1 ADNI data collection and sharing for this project was funded by the Alzheimer's Disease 2 Neuroimaging Initiative (ADNI) (National Institutes of Health Grant U01 AG024904) and DOD 3 ADNI (Department of Defense award number W81XWH-12-2-0012). ADNI is funded by the 4 National Institute on Aging, the National Institute of Biomedical Imaging and Bioengineering, and 5 through generous contributions from the following: AbbVie, Alzheimer's Association; Alzheimer's Drug Discovery Foundation; Araclon Biotech; BioClinica, Inc.; Biogen; Bristol-6 7 Myers Squibb Company; CereSpir, Inc.; Cogstate; Eisai Inc.; Elan Pharmaceuticals, Inc.; Eli Lilly 8 and Company; EuroImmun; F. Hoffmann-La Roche Ltd and its affiliated company Genentech, 9 Inc.; Fujirebio; GE Healthcare; IXICO Ltd.; Janssen Alzheimer Immunotherapy Research & 10 Development, LLC.; Johnson & Johnson Pharmaceutical Research & Development LLC.; 11 Lumosity; Lundbeck; Merck & Co., Inc.; Meso Scale Diagnostics, LLC.; NeuroRx Research; 12 Neurotrack Technologies; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Piramal Imaging; 13 Servier; Takeda Pharmaceutical Company; and Transition Therapeutics. The Canadian Institutes 14 of Health Research is providing funds to support ADNI clinical sites in Canada. Private sector 15 contributions are facilitated by the Foundation for the National Institutes of Health 16 (www.fnih.org). The grantee organization is the Northern California Institute for Research and Education, and the study is coordinated by the Alzheimer's Therapeutic Research Institute at the 17 18 University of Southern California. ADNI data are disseminated by the Laboratory for Neuro

19

Imaging at the University of Southern California.

1 **ABSTRACT** 2 Objective: Brain atrophy is associated with degenerative neuropathologies as well as clinical 3 status of dementia. Whether dementia influences atrophy independent of neuropathologies is not 4 known. In this study, we examined the pattern of atrophy associated with dementia while 5 accounting for the most common dementia-related neuropathologies. 6 Methods: We used data from National Alzheimer's Coordinating Center (NACC, N=129) and 7 Alzheimer's Disease Neuroimaging Initiative (ADNI, N=47) participants with suitable in-vivo 8 3D-T1w MRI and autopsy data. We determined dementia status at visit closest to MRI. We 9 examined the following dichotomized neuropathological variables: Alzheimer's disease 10 hippocampal sclerosis, Lewy Bodies, neuropathology, cerebral amyloid angiopathy, atherosclerosis. Voxel-based morphometry (VBM) identified areas associated with dementia after 12 accounting for neuropathologies. Identified regions of interest were further analyzed. We used 13 multiple linear regression models adjusted for neuropathologies and demographic variables. 14 **Results:** We found strong associations for dementia with volumes of the hippocampus, amygdala, 15 and parahippocampus (semi-partial correlations \geq 0.28, P<0.0001 for all regions in NACC; semi-16 partial correlations ≥ 0.35 , P ≤ 0.01 for hippocampus and parahippocampus in ADNI). Dementia 17 status accounted for more unique variance in atrophy in these structures (~8%) compared with 18 neuropathological variables; the only exception was hippocampal sclerosis which accounted for 19 more variance in hippocampal atrophy (10%). 20 Conclusion: Even after accounting for the most common neuropathologies, dementia still had among the strongest correlations with atrophy of medial temporal lobe structures. This suggests

that atrophy of the medial temporal lobe is most related to clinical status of dementia as opposed

11

21

22

23

to Alzheimer's or other neuropathologies.

INTRODUCTION

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

Some of the earliest imaging biomarkers proposed for Alzheimer's disease (AD) were measures of brain atrophy. In 1988, Seab et al reported a 40% reduction in hippocampal volume in AD patients compared to control participants¹. In 1989, De Leon et al found that in participants with symptoms of dementia, hippocampal atrophy, as assessed on computed tomography (CT) images, was more prevalent². Since then, many studies have found associations between atrophy of brain regions and clinical AD, including some recurring regions such as structures of the medial temporal, lateral temporal, and parietal lobes, and these atrophy measures have been used for both diagnosis³ and as research biomarkers⁴ for AD. Previous studies have also examined the association between brain atrophy, as assessed on imaging, and various neurodegenerative pathologies. An early study found that MRI- and autopsymeasured atrophy of the hippocampus were highly correlated and associated with lower hippocampal neuron counts⁵. Another early imaging-pathology correlation study, using participants from the Nun Study, found that hippocampal atrophy was significantly associated with Braak staging of neurofibrillary tangles⁶. Additional studies have found associations between AD neuropathology (ADNP) and whole brain as well as hippocampal atrophy, while other neuropathologies, such as hippocampal sclerosis of aging (HS) and TAR DNA-binding protein 43 (TDP-43), have also been found to be associated with hippocampal volumes and medial temporal lobe atrophy⁷. Only a few studies have examined the association between atrophy on neuroimaging and clinical dementia while accounting for neuropathologies. The objective of this study was to examine the association between MRI-measured antemortem gray matter atrophy and clinical status of dementia while accounting for commonly assessed neuropathologies found at autopsy.

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

6

To address this question we used data from participants with appropriate MRI and neuropathology data from the National Alzheimer's Coordinating Center (NACC) as an exploration dataset, and the Alzheimer's Disease Neuroimaging Initiative (ADNI) database as a validation dataset. **METHODS** Exploration dataset, NACC: We used data from participants with and without dementia, who had both MRI and pathology data available in the NACC database between September 2005 and March 2017. The NACC Uniform Data Set (UDS) consists of data submitted by approximately 30 National Institute on Aging (NIA) funded Alzheimer's Disease Research Centers (ADRCs) across the USA⁸. Contributing ADRCs are approved by their local IRB. We identified 243 participants with both pathology data and at least one available MRI, and used 129 for our analyses (see MRI methods section below). Demographic and Clinical Variables, NACC Data: We selected dementia status, assigned by ADRC clinicians as either dementia of the Alzheimer's type or other non-Alzheimer's dementia, at the assessment closest to MRI as our variable of interest. We also selected the following demographic variables: sex, age at MRI, years from MRI to death, and years of education. We used Mini-Mental State Examination (MMSE) and Clinical Dementia Rating Sum of Boxes (CDR-SB) instead of dementia status for some analyses. Pathology: Neuropathological data are collected at the ADRCs via a standardized Neuropathology Form and Coding Guidebook^{9, 10}. The NACC pathology data dictionary was used to define pathological categories. We assessed Alzheimer's Disease neuropathology (ADNP), which we defined as present (+) based on high likelihood per the NIA-Reagan criteria¹¹, comprising a

combined Consortium to Establish a Registry for Alzheimer's Disease (CERAD) neuritic plaque

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

7

score of 3 (Frequent) and high Braak stage for neurofibrillary tangles (V/VI). We assessed hippocampal sclerosis (HS), defined as present/absent (+/-) based on either NPHIPSCL (NACC pathology form version 10), categorizing HS as present or absent (+/-) in the CA1 and/or subiculum, and NPSCL (NACC pathology form version 9 and earlier), categorizing medial temporal lobe sclerosis as present or absent (+/-) including hippocampal sclerosis. We also assessed: cerebral amyloid angiopathy (CAA) defined as none/mild (-) and moderate/severe (+); Lewy bodies, which we dichotomized as present/absent (+/-) based on presence in any region assessed; and atherosclerosis defined as none/mild (-) and moderate/severe (+). There was limited availability of hippocampal TDP-43 information for the participants in the data-freeze of NACC used for this study (23 of 129, or 18% of participants), and thus TDP-43 was not included for analyses. However, TDP-43 data was available for more ADNI participants and used for supplemental analysis (see ADNI section below). We also used the full range of severity (for atherosclerosis and CAA) and staging (for Braak tangles and CERAD plaques) scores as continuous variables for some analyses. MRI: Supplementary Figure-1 shows a flow chart for inclusion and exclusion criteria of NACC participants. Out of the 243 participants with both pathology and at least one MRI available, 29 did not have a 3D-T1w scan. We made the decision to limit the data to scans that utilized an inversion-recovery (IR) preparation pulse, since this has a large effect on tissue contrast, especially between gray matter and white matter^{12, 13}. There were no differences between participants with IR compared to non-IR sequences, which we report in the **Supplementary Methods**. Restricting the scans to those with IR sequences excluded another 74 participants rendering a sample of 140 participants with appropriate scans. To reduce time from scan to autopsy, for each participant we used the last available scan of sufficient quality.

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

8

(adni.loni.usc.edu) was launched in 2003, led by Principal Investigator Michael W. Weiner, MD,

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

9

and has acquired serial MRI, positron emission tomography (PET), other biological markers, and clinical and neuropsychological assessment, to study the progression of mild cognitive impairment (MCI) and early Alzheimer's disease (AD). For up-to-date information, see www.adni-info.org. We selected ADNI-1 participants because the majority of participants with pathology data (47 out of 64 in the April 2018 public release) were ADNI-1. Additionally, the ADNI-1 MRI protocol consisted of an MPRAGE sequence on 1.5T scanners that renders the sequences more comparable across scanners. We used the clinical classification of AD according to ADNI criteria 17 as our dementia variable. Briefly, physicians classified participants as AD based on clinical assessment, an MMSE score of less than 26, a clinical dementia rating (CDR) score of 0.5 or greater, and meeting NINCDS/ADRDA criteria¹⁸ for probable AD. We used the MRI closest to death for our analyses. Because ADNI neuropathology data are acquired following the NACC guidelines and forms (v10), we used the same neuropathological variables described in the *Pathology* Methods section above, with NPHIPSCL as the only variable for HS. For a supplemental analysis we used TDP-43 in the hippocampus (NPTDPC variable) which was available for a larger proportion of participants in ADNI (43 of 47, 91%) than NACC (18%). Statistics: To examine whether gray matter volume was associated with clinical status of dementia while accounting for neuropathologies, we performed a VBM analysis in the NACC dataset using multiple linear regression models on a voxel-wise basis, with dementia status, dichotomized neuropathological variables, sex, age at MRI, years of education, years from MRI to death, and TIV, as covariates. We used a voxel-wise threshold of P=0.001 and a cluster-size family-wise error rate threshold of P=0.05. Based on the voxel-wise VBM results, we then explored the relationship between the volumes of the various ROIs, as the dependent variables, with the demographic and neuropathological variables via multiple linear regression models. To verify the effects found

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

10

simplified statistical models by limiting the number of covariates to those found to be significantly associated (P<0.05) with the volumes of the ROIs in the NACC dataset. We compared the semi-partial correlation coefficients between the NACC and ADNI datasets as estimates of effect size and directionality. We next performed this same comparison except replacing the ADNP variable with Braak stage dichotomized as present for V/VI, as well as dichotomized by present for Braak stage of III/IV/V/VI. Lastly, we examined whether semi-partial correlation coefficients differed when using TDP-43 instead of HS, or when using both TDP-43 and HS in the same multiple linear regression.

Data Availability: NACC and ADNI data are freely available to researchers upon request.

RESULTS

Participant Characteristics, NACC: The characteristics for the NACC participants are summarized in Table-1. There were 129 participants, most of whom presented with dementia at the time of MRI (94, 73%). Participants with dementia were significantly younger at time of MRI, were more likely to have ADNP, a higher Braak stage, higher CERAD neuritic plaque score, Lewy bodies, and more severe CAA. The 10th/90th percentiles for age at MRI were 62years/85years for those with dementia and 70years/92years for those without dementia. There were no significant differences in terms of sex or years of education. Of note, around 75% of the participants without dementia had MCI at the time of MRI.

VBM Voxel-wise results*, NACC: We observed strong associations between gray matter density and dementia in the hippocampus, amygdala, and adjacent temporal cortex, even after accounting for other demographic and neuropathological variables, with stronger associations in the left hemisphere (left cluster size=27.3mL, right cluster size=12.3mL, cluster-size family-wise error rate P<0.001 for both; Figure-1.A). The bilateral Harvard-Oxford regions with the highest percentage overlap with the VBM results (thresholded at P=0.001) were the amygdala (81%),

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

12

hippocampus (64%), anterior parahippocampus (41%), and posterior parahippocampus (31%), Figure-1.B). The only other regions with significant overlap were the temporal pole (30%) and temporal fusiform gyrus (12%). We selected the medial temporal regions of the hippocampus, amygdala, and parahippocampus (consisting of the anterior and posterior parahippocampal regions) as ROIs to be used for further analysis. For comparison, we display VBM results that did not include neuropathological variables (using demographic variables only) in Supplementary Figure-2, which shows a similar pattern but with larger significant clusters that extend beyond the medial temporal lobe to the adjacent inferior and lateral temporal, as well as orbitofrontal lobes. ROI Analysis, NACC: The volumes of the ROIs (hippocampus, amygdala, parahippocampus) all showed significant and strong negative associations with dementia status, and when examining the unique variance explained by each of the variables, we found that dementia status had the strongest association for all the regions, accounting for the most unique variance (~ 8%, **Table-2**). The one exception to this was HS, which accounted for more variance of hippocampal volume (~10%). Additionally, we found significant associations between the volumes of these ROIs and age (greater atrophy with age), as well as TIV (greater intracranial volume associated with greater ROI volume). With regards to neuropathologies, the only significant associations with dementia were negative correlations between all ROIs and HS (strongest in the hippocampus with unique variance explained at $\sim 10\%$, lower in the other regions at $\sim 3\%$), and a negative correlation of amygdala volume with ADNP (2.3% variance explained) and Lewy bodies (2.9% variance explained). Adding dementia status to the models that already included the other variables increased the adjusted R² from 0.34 to 0.42 for hippocampus, 0.35 to 0.43 for amygdala, and 0.27 to 0.35 for parahippocampus, and variance inflation factors for the model did not exceed 2 for any of the

variables. Results were similar when using continuous instead of dichotomized measures for

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

13

of the findings for the neuropathological variables (ADNP and HS) were consistent for the ADNI

and NACC datasets and broadly showed a similar magnitude, though ADNP had a larger (though not statistically significant) semi-partial correlation for each of the regions in the ADNI dataset. When using dichotomized Braak stage instead of ADNP, the trends were largely similar, with nearly identical findings when using Braak Stage V/VI or Braak stage III/IV/V/VI classifications (Supplementary Table-2). Lastly, the effect of dementia did not change when using TDP-43 instead of HS or when using both in the same model (Supplementary Table-3). TDP-43 tended to show similar effects when used instead of HS but the semi-partial correlations for TDP-43 and adjusted R² for the model were lower, and when including both TDP-43 and HS in the same model

DISCUSSION

HS tended to eclipse the effects of TDP-43.

We examined the relationship between gray matter atrophy and clinical dementia status while accounting for other demographic and commonly-assessed neuropathological variables using the NACC and ADNI databases. We found a strong association between dementia and atrophy of medial temporal lobe structures, namely the hippocampus, amygdala, and parahippocampus, even after accounting for neuropathologies. This association of medial temporal lobe atrophy with dementia was stronger than for any other demographic or neuropathological variables, except for hippocampal sclerosis in relation to hippocampal volume. We found similar direction and size for the effect of dementia on atrophy for: 1) models using both dichotomized and continuous measures for neuropathologies, 2) for both dementia status as well as more continuous measures of cognitive burden (MMSE and CDR-SB), 3) for hippocampal volumes generated from three different pipelines (CAT12, FreeSurfer, ASHS), 4) for subsets of participants with more homogeneous MRI acquisitions, and 5) across two different imaging-pathology

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

15

on atrophy⁶. Another study examined the relationship between MRI-derived hippocampal volumes

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

16

In our analysis of the NACC data that included more participants than any previous studies, after accounting for dementia, the presence of ADNP was either weakly or not significantly associated with volumes of the medial temporal lobe structures. This result was true when using

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

17

A recent study examining hippocampal volumes on postmortem MRI using Religious Orders Study (ROS) and Memory and Aging Project (MAP) data found that, after accounting for demographic and neuropathological variables, the addition of hippocampal volumes to their models explained an additional 5% in the variance of cognitive decline in participants³⁰. Our results are in agreement with the ROS/MAP study. Additionally, we believe our study contributes the following: 1) In our study, we examined the contribution of dementia and neuropathologies to gray matter atrophy on brain MRI. The ROS/MAP study examined the contribution of hippocampal volume on MRI to cognitive decline in an attempt to investigate the mechanisms

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

18

accounting for dementia. This finding underscores the relevance of hippocampal volume as a potential biomarker for HS. Additionally, our analyses in a subset of ADNI participants with TDP-43 information indicated that while TDP-43 behaves similar to HS, its effects are weaker. However, this analysis was in a smaller subset of participants and represents a limitation in this

study: further research in larger datasets should examine medial temporal lobe atrophy in relation

to cognition while accounting for more complete TDP-43 staging.

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

One of the limitations of this study is the heterogeneity of the MRI data, specifically in the NACC dataset. We did, however, limit the sequence paradigms used in the analysis to those that implemented an inversion recovery pulse, as it results in the greatest difference in tissue contrast. We also performed analyses limited to subsets of more homogeneous scans and the associations in these analyses tended to be slightly stronger and appeared to confirm the results in the full dataset. Additionally, the ADNI dataset circumvented some of these confounding factors by implementing a similar sequence across different scan vendors, all at 1.5T. Also, the similar strength of associations with cognitive status in both datasets (a more heterogeneous and a more homogeneous sample) highlights the robustness of our finding and the potential clinical application of the results. Another limitation to this study is the high proportion of participants with dementia and with high Braak stage and CERAD neuritic plaque scores in the NACC data freeze used. While the ADNI dataset partially circumvented this issue, further studies should examine these relationships in datasets with a more balanced proportion of participants without dementia and lower ADNP pathology burden. However, this is a limitation present in many neuropathology datasets where a large proportion of participants have dementia and a high ADNP burden. One final limitation of the study is one that is germane to most dementia research in that the participants used in this study are not necessarily a representative sample of the community, limiting generalizability. In conclusion, we found a significant association between atrophy of medial temporal lobe structures, namely the hippocampus, amygdala, and parahippocampus, and clinical status of dementia, even while accounting for many of the commonly-assessed neuropathologies. This association of medial temporal lobe atrophy with dementia was stronger than any other demographic or neuropathological variable, with the exception of hippocampal sclerosis in relation

hippocampal volume but was weakly associated with amygdala volume in our models. These

3 findings have significant implications on the diagnostic utility of MRI in dementia clinics and

confirm the significant pathology-independent relationship between dementia and atrophy of

5 structures that are generally considered to be the hallmark of Alzheimer's disease.

2

4

MRI to death, and years of education) are reported as mean and standard deviations within each

group and group differences are assessed by Student's T-test. Categorical variables (sex, MCI, and

pathological variables) are reported as number and percentage within each group and group

differences are assessed by Chi-Squared tests. †Five participants with dementia were missing

6 MMSE score. MCI: Mild cognitive impairment. MMSE: Mini-Mental State Examination. CDR-

SB: Clinical Dementia Rating Sum of Boxes. ADNP: Alzheimer's disease neuropathology.

8 CERAD: Consortium to Establish a Registry for Alzheimer's Disease. HS: Hippocampal Sclerosis.

9 CAA: Cerebral amyloid angiopathy. Edu.: education.

2

3

4

5

7

10

11

12

| Variable | Participants without Dementia (N=35) | Participants with Dementia (N=94) |
|-----------------------|--|---|
| Males | 23 (66%) | 66 (70%) |
| Age at MRI | 82 (±9) years | 75 (±9) years |
| Years Edu. | 16 (±3) years | 16 (±3) years |
| MCI | 26 (74%) | |
| MMSE | 26.7 (±2.6) | 18.8 (±6.4)† |
| CDR-SB | 1.7 (±1.7) | 7.7 (±4.2) |
| Years MRI to Death | 4 (±2) years | 3 (±2) years |
| ADNP | 11 (31%) | 61 (65%) |
| Braak Stage 0/I/II | 4 (11%) | 2 (2%) |
| Braak Stage III/IV | 8 (23%) | 12 (13%) |
| Braak Stage V/VI | 23 (66%) | 80 (85%) |
| CERAD plaque 0 | 2 (6%) | 3 (3%) |
| CERAD plaque 1 | 2 (6%) | 1 (1%) |
| CERAD plaque 2 | 18 (51%) | 27 (29%) |
| CERAD plaque 3 | 13 (37%) | 63 (67%) |
| HS | 6 (17%) | 16 (15%) |
| Lewy Bodies | 10 (29%) | 49 (52%) |
| CAA | 11 (31%) | 64 (68%) |
| Atherosclerosis | 14 (40%) | 30 (32%) |

| Chi-square or T-test P- Value | | | |
|-------------------------------------|--|--|--|
| 0.6 | | | |
| <0.001 | | | |
| 0.8 | | | |
| | | | |
| <0.001 | | | |
| <0.001 | | | |
| 0.08 | | | |
| <0.001 | | | |
| 0.02 | | | |
| 0.02 | | | |
| 0.7 | | | |
| 0.049 | | | |
| 0.02 | | | |
| 0.3 | | | |
| 0.3 | | | |

21

Table-2. Multiple linear regression results for ROI volumes across the various demographic and neuropathological measures for the NACC data (N=129). Bold denotes P<0.05. TIV: total intracranial volume. ADNP: Alzheimer's disease neuropathology. HS: Hippocampal Sclerosis. CAA: Cerebral amyloid angiopathy. Semi-Part.: semi-partial correlation coefficient. Var. Exp.: unique variance explained.

| | Regions | <i>Hippocampus</i> | | | |
|-------------|--|--------------------|-------------|-------|--------|
| ١ | /ariables Semi- % Var. Part. Exp. T-stat | | P- value | | |
| ပ | Dementia Status at MRI | -0.28 | 7.78 | -4.15 | <0.001 |
| Demographic | Age | -0.27 | 7.51 | -4.08 | <0.001 |
| ıra | Sex | 0.05 | 0.20 | 0.67 | 0.5 |
| 109 | Years Education | 0.13 | 1.59 | 1.88 | 0.06 |
| Jen | Years MRI to Death | 0.11 | 1.25 | 1.67 | 0.1 |
| 7 | TIV | 0.19 | 3.61 | 2.84 | 0.005 |
| | ADNP | -0.06 | 0.41 | -0.96 | 0.3 |
| og) | HS | -0.31 | 9.73 | -4.65 | <0.001 |
| lot | Lewy Bodies | -0.04 | 0.13 | -0.54 | 0.6 |
| Pathology | CAA | -0.03 | 0.08 | -0.44 | 0.7 |
| 1 | Atherosclerosis | -0.07 | 0.44 | -0.98 | 0.3 |

| Amygdala | | | | |
|----------|--------|--------|--------|--|
| Semi- | % Var. | T-stat | P- | |
| Part. | Ехр. | ı-sıaı | value | |
| -0.29 | 8.24 | -4.30 | <0.001 | |
| -0.24 | 5.95 | -3.65 | <0.001 | |
| -0.04 | 0.18 | -0.64 | 0.5 | |
| 0.12 | 1.42 | 1.78 | 0.08 | |
| 0.09 | 0.88 | 1.41 | 0.2 | |
| 0.19 | 3.50 | 2.80 | 0.006 | |
| -0.15 | 2.31 | -2.27 | 0.03 | |
| -0.19 | 3.42 | -2.77 | 0.006 | |
| -0.17 | 2.92 | -2.56 | 0.01 | |
| 0.12 | 1.46 | 1.81 | 0.07 | |
| -0.08 | 0.67 | -1.22 | 0.2 | |

| | Parahippocampus | | | |
|-------|-----------------|--------|--------|--|
| Semi- | % Var. | T atat | P- | |
| Part. | Ехр. | T-stat | value | |
| -0.28 | 7.73 | -3.91 | <0.001 | |
| -0.25 | 6.30 | -3.52 | <0.001 | |
| -0.12 | 1.35 | -1.62 | 0.1 | |
| 0.04 | 0.12 | 0.49 | 0.6 | |
| 0.11 | 1.10 | 1.48 | 0.1 | |
| 0.15 | 2.28 | 2.13 | 0.04 | |
| -0.06 | 0.35 | -0.83 | 0.4 | |
| -0.17 | 2.79 | -2.35 | 0.02 | |
| -0.09 | 0.79 | -1.25 | 0.2 | |
| 0.05 | 0.23 | 0.68 | 0.5 | |
| -0.08 | 0.59 | -1.08 | 0.3 | |

Table-3. Multiple linear regression results for ROI volumes using full severity (CAA and atherosclerosis) or staging (Braak and CERAD) information as continuous variables in the NACC data (N=129). Bold denotes P<0.05. TIV: total intracranial volume. ADNP: Alzheimer's disease neuropathology. HS: Hippocampal Sclerosis. CERAD: Consortium to Establish a Registry for Alzheimer's Disease. CAA: Cerebral amyloid angiopathy. Semi-Part.: semi-partial correlation coefficient. Var. Exp.: unique variance explained.

| | Regions | s Hippocampus | | | |
|-------------|------------------------|-----------------------------------|-------|-------------|--------|
| ١ | /ariables | Semi- % Var. Part. Exp. T-stat | | P- value | |
| ပ | Dementia Status at MRI | -0.29 | 8.18 | -4.23 | <0.001 |
| Demographic | Age | -0.32 | 10.50 | -4.79 | <0.001 |
| ıra | Sex | 0.03 | 0.10 | 0.46 | 0.6 |
| 109 | Years Education | 0.13 | 1.64 | 1.89 | 0.06 |
| Jen | Years MRI to Death | 0.09 | 0.76 | 1.28 | 0.2 |
| 7 | TIV | 0.18 | 3.10 | 2.60 | 0.01 |
| | Braak Stage | -0.05 | 0.23 | -0.71 | 0.5 |
| 97 | CERAD Plaques | 0.01 | 0.01 | 0.14 | 0.9 |
| Pathology | HS | -0.30 | 8.88 | -4.41 | <0.001 |
| the | Lewy Bodies | -0.04 | 0.14 | -0.55 | 0.6 |
| Pa | CAA | -0.05 | 0.22 | -0.70 | 0.5 |
| | Atherosclerosis | -0.04 | 0.18 | -0.63 | 0.5 |

| Amygdala | | | |
|----------|--------|--------|--------|
| Semi- | % Var. | T -4-4 | P- |
| Part. | Ехр. | T-stat | value |
| -0.30 | 8.88 | -4.38 | <0.001 |
| -0.30 | 8.94 | -4.40 | <0.001 |
| -0.03 | 0.07 | -0.38 | 0.7 |
| 0.11 | 1.10 | 1.54 | 0.1 |
| 0.08 | 0.56 | 1.11 | 0.3 |
| 0.22 | 4.62 | 3.16 | 0.002 |
| 0.02 | 0.03 | 0.25 | 8.0 |
| -0.14 | 1.88 | -2.02 | 0.046 |
| -0.20 | 3.92 | -2.92 | 0.004 |
| -0.15 | 2.25 | -2.20 | 0.03 |
| 0.09 | 0.74 | 1.26 | 0.2 |
| -0.02 | 0.04 | -0.31 | 0.8 |

| | Parahipp | ocampus | ; |
|-------|----------|---------|--------|
| Semi- | % Var. | T-stat | P- |
| Part. | Ехр. | 1-3เฉเ | value |
| -0.27 | 7.08 | -3.74 | <0.001 |
| -0.30 | 9.24 | -4.28 | <0.001 |
| -0.14 | 1.85 | -1.92 | 0.06 |
| 0.05 | 0.20 | 0.64 | 0.5 |
| 0.08 | 0.67 | 1.16 | 0.3 |
| 0.13 | 1.64 | 1.80 | 0.07 |
| -0.11 | 1.19 | -1.53 | 0.1 |
| 0.03 | 0.11 | 0.47 | 0.6 |
| -0.15 | 2.22 | -2.10 | 0.04 |
| -0.09 | 0.79 | -1.26 | 0.2 |
| 0.04 | 0.18 | 0.59 | 0.6 |
| -0.06 | 0.41 | -0.90 | 0.4 |

Table-4. Semi-partial correlation coefficients for ROI volumes using progressively more homogeneous scan subsets. Bold denotes P<0.05. TIV: total intracranial volume. ADNP: Alzheimer's disease neuropathology. HS: Hippocampal Sclerosis. CAA: Cerebral amyloid angiopathy.

| | Regions | Hippocampus | | |
|-------------|------------------------|-------------------|------------------|------------------------|
| \ | /ariables | All IR (N=129) | MPRAGE (N=74) | MPRAGE 3T (N=54) |
| ပ | Dementia Status at MRI | -0.28 | -0.39 | -0.35 |
| hi | Age | -0.27 | -0.23 | -0.32 |
| Ira | Sex | 0.05 | -0.02 | -0.02 |
| Demographic | Years Education | 0.13 | 0.17 | 0.22 |
| Jen | Years MRI to Death | 0.11 | 0.08 | 0.04 |
| 7 | TIV | 0.19 | 0.12 | 0.10 |
| | ADNP | -0.06 | -0.01 | -0.06 |
| og) | HS | -0.31 | -0.37 | -0.40 |
| 101 | Lewy Bodies | -0.04 | 0.03 | 0.06 |
| Pathology | CAA | -0.03 | -0.03 | 0.01 |
| _ | Atherosclerosis | -0.07 | -0.10 | 0.01 |

| Amygdala | | | | |
|-------------------|------------------|------------------------|--|--|
| All IR (N=129) | MPRAGE (N=74) | MPRAGE 3T (N=54) | | |
| -0.29 | -0.34 | -0.30 | | |
| -0.24 | -0.23 | -0.26 | | |
| -0.04 | -0.02 | 0.00 | | |
| 0.12 | 0.09 | 0.11 | | |
| 0.09 | 0.02 | -0.02 | | |
| 0.19 | 0.28 | 0.29 | | |
| -0.15 | -0.05 | -0.06 | | |
| -0.19 | -0.23 | -0.24 | | |
| -0.17 | -0.15 | -0.17 | | |
| 0.12 | 0.10 | 0.11 | | |
| -0.08 | -0.07 | -0.01 | | |

| Parahippocampus | | | | |
|-------------------|------------------|------------------------|--|--|
| All IR (N=129) | MPRAGE (N=74) | MPRAGE 3T (N=54) | | |
| -0.28 | -0.35 | -0.29 | | |
| -0.25 | -0.24 | -0.37 | | |
| -0.12 | -0.10 | -0.02 | | |
| 0.04 | 0.09 | 0.12 | | |
| 0.11 | -0.01 | -0.06 | | |
| 0.15 | 0.18 | 0.22 | | |
| -0.06 | 0.04 | -0.02 | | |
| -0.17 | -0.25 | -0.26 | | |
| -0.09 | -0.10 | -0.08 | | |
| 0.05 | 0.09 | 0.05 | | |
| -0.08 | -0.10 | 0.03 | | |

Table-5. Participant characteristics of ADNI data. Continuous variables (age at MRI, years from MRI to death) are reported as mean and standard deviation within each group and group differences are assessed by Student's T-test. Categorical variables (sex and pathological variables) are reported as number and percentage within each group and group differences are assessed by Chi-Squared tests. †Two participants with and two participants without dementia were missing TDP-43 information in the hippocampus. MCI: Mild Cognitive Impairment. ADNP: Alzheimer's Disease Neuropathology. CERAD: Consortium to Establish a Registry for Alzheimer's Disease. HS: Hippocampal Sclerosis. TDP-43: TAR DNA-binding protein 43. Hipp.: Hippocampus.

| Variable | Participants without Dementia (N=11) | Participants with Dementia (N=36) | Chi-square or T-test P- Value |
|---------------------------|--|---|-------------------------------------|
| Males | 9 (82%) | 24 (67%) | 0.8 |
| Age at MRI | 84 (±4) years | 80 (±6) years | 0.1 |
| MCI | 9 (88%) | NA | |
| Years MRI to Death | 3 (±2) years | 2 (±2) years | 0.2 |
| ADNP | 5 (45%) | 24 (67%) | 0.2 |
| Braak tangle Stage 0/I/II | 2 (18%) | 9 (25%) | 0.1 |
| Braak tangle Stage III/IV | 2 (18%) | 1 (3%) | |
| Braak tangle Stage V/VI | 7 (64%) | 26 (72%) | |
| CERAD amyloid plaque 0 | 3 (27%) | 5 (14%) | 0.2 |
| CERAD amyloid plaque 1 | 1 (9%) | 6 (17%) | |
| CERAD amyloid plaque 2 | 2 (18%) | 1 (3%) | |
| CERAD amyloid plaque 3 | 5 (45%) | 24 (67%) | |
| HS | 2 (18%) | 4 (11%) | 0.5 |
| Lewy Bodies | 5 (45%) | 16 (44%) | 0.6 |
| TDP-43 Hipp. | 3 (33%)† | 14 (41%)† | 0.7 |


Table-6. Comparison of NACC (N=129) and ADNI (N=47) semi-partial correlation coefficients for ROI volumes across the various demographic and neuropathological measures. Bold denotes P<0.05. ROI: Region of interest. TIV: total intracranial volume. ADNP: Alzheimer's disease neuropathology. HS: Hippocampal Sclerosis. Semi-Part.: semi-partial correlation coefficient.

| Regions | Hippod Semi-Pa | ampus art. Corr. |
|-------------|-------------------|---------------------|
| Variables | NACC | ADNI |
| Dementia | -0.34 | -0.35 |
| Age | -0.37 | 0.11 |
| TIV | 0.28 | 0.23 |
| ADNP | -0.05 | -0.18 |
| HS | -0.28 | -0.47 |
| Lewy Bodies | -0.05 | -0.29 |

| Amygdala Semi-Part. Corr. | | |
|------------------------------|-------|--|
| NACC | ADNI | |
| -0.30 | -0.21 | |
| -0.34 | 0.12 | |
| 0.38 | 0.19 | |
| -0.15 | -0.21 | |
| -0.18 | -0.28 | |
| -0.17 | -0.27 | |

| Parahippocampus Semi-Part. Corr. | | |
|-------------------------------------|-------|--|
| NACC | ADNI | |
| -0.31 | -0.35 | |
| -0.34 | 0.11 | |
| 0.33 | 0.09 | |
| -0.05 | -0.21 | |
| -0.17 | -0.35 | |
| -0.07 | -0.22 | |

Figure-1. Voxel-wise VBM association gray matter atrophy with dementia in NACC data (N=129). Results thresholded at T-stat=3.16 (P=0.001) and survive cluster-wise false discovery rate threshold of 0.05. A) Strong associations present in the medial temporal lobe, with larger effects in the left hemisphere. B) Zoomed-in voxel-wise maps in left hemisphere with outlines of Harvard-Oxford atlas regions of the hippocampus (light green), amygdala (light blue), and parahippocampus (pink) illustrating degree of overlap between thresholded T-statistic maps and these regions. VBM: Voxel-based morphometry.



REFERENCES

- 1. Seab JP, Jagust WJ, Wong ST, Roos MS, Reed BR, Budinger TF. Quantitative NMR measurements of hippocampal atrophy in Alzheimer's disease. Magn Reson Med 1988;8:200-208.
- 2. de Leon MJ, George AE, Stylopoulos LA, Smith G, Miller DC. Early marker for Alzheimer's disease: the atrophic hippocampus. Lancet 1989;2:672-673.
- 3. Weiner M, Khachaturian Z. The use of MRI and PET for clinical diagnosis of dementia and investigation of cognitive impairment: a consensus report. Alzheimer's Assoc Chicago, IL 2005;1:1-15.
- 4. Marquez F, Yassa MA. Neuroimaging Biomarkers for Alzheimer's Disease. Mol Neurodegener 2019;14:21.
- 5. Bobinski M, de Leon MJ, Wegiel J, et al. The histological validation of post mortem magnetic resonance imaging-determined hippocampal volume in Alzheimer's disease. Neuroscience 2000;95:721-725.
- 6. Gosche KM, Mortimer JA, Smith CD, Markesbery WR, Snowdon DA. Hippocampal volume as an index of Alzheimer neuropathology: findings from the Nun Study. Neurology 2002;58:1476-1482.
- 7. Dallaire-Theroux C, Callahan BL, Potvin O, Saikali S, Duchesne S. Radiological-Pathological Correlation in Alzheimer's Disease: Systematic Review of Antemortem Magnetic Resonance Imaging Findings. J Alzheimers Dis 2017;57:575-601.
- 8. Morris JC, Weintraub S, Chui HC, et al. The Uniform Data Set (UDS): clinical and cognitive variables and descriptive data from Alzheimer Disease Centers. Alzheimer Dis Assoc Disord 2006;20:210-216.
- 9. Beekly DL, Ramos EM, van Belle G, et al. The National Alzheimer's Coordinating Center (NACC) Database: an Alzheimer disease database. Alzheimer Dis Assoc Disord 2004;18:270-277.
- 10. Besser LM, Kukull WA, Teylan MA, et al. The Revised National Alzheimer's Coordinating Center's Neuropathology Form-Available Data and New Analyses. J Neuropathol Exp Neurol 2018;77:717-726.
- 11. Consensus recommendations for the postmortem diagnosis of Alzheimer's disease. The National Institute on Aging, and Reagan Institute Working Group on Diagnostic Criteria for the Neuropathological Assessment of Alzheimer's Disease. Neurobiol Aging 1997;18:S1-2.
- 12. Han X, Jovicich J, Salat D, et al. Reliability of MRI-derived measurements of human cerebral cortical thickness: the effects of field strength, scanner upgrade and manufacturer. Neuroimage 2006;32:180-194.
- 13. Ellingson BM, Bendszus M, Boxerman J, et al. Consensus recommendations for a standardized Brain Tumor Imaging Protocol in clinical trials. Neuro Oncol 2015;17:1188-1198.
- 14. Gaser C, Dahnke R. CAT-a computational anatomy toolbox for the analysis of structural MRI data. HBM 2016;2016:336-348.
- 15. Iglesias JE, Augustinack JC, Nguyen K, et al. A computational atlas of the hippocampal formation using ex vivo, ultra-high resolution MRI: Application to adaptive segmentation of in vivo MRI. Neuroimage 2015;115:117-137.
- 16. Xie L, Wisse LEM, Pluta J, et al. Automated segmentation of medial temporal lobe subregions on in vivo T1-weighted MRI in early stages of Alzheimer's disease. Hum Brain Mapp 2019;40:3431-3451.

- 17. Petersen RC, Aisen PS, Beckett LA, et al. Alzheimer's Disease Neuroimaging Initiative (ADNI): clinical characterization. Neurology 2010;74:201-209.
- 18. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984;34:939-944.
- 19. Warner RM. Applied statistics: From bivariate through multivariate techniques: Sage Publications, 2012.
- 20. Svenningsson AL, Stomrud E, Insel PS, Mattsson N, Palmqvist S, Hansson O. beta-amyloid pathology and hippocampal atrophy are independently associated with memory function in cognitively healthy elderly. Sci Rep 2019;9:11180.
- 21. Khosravi M, Peter J, Wintering NA, et al. 18F-FDG Is a Superior Indicator of Cognitive Performance Compared to 18F-Florbetapir in Alzheimer's Disease and Mild Cognitive Impairment Evaluation: A Global Quantitative Analysis. J Alzheimers Dis 2019;70:1197-1207.
- 22. Han SD, Gruhl J, Beckett L, et al. Beta amyloid, tau, neuroimaging, and cognition: sequence modeling of biomarkers for Alzheimer's Disease. Brain Imaging Behav 2012;6:610-620.
- 23. Silbert LC, Quinn JF, Moore MM, et al. Changes in premorbid brain volume predict Alzheimer's disease pathology. Neurology 2003;61:487-492.
- 24. Erten-Lyons D, Woltjer RL, Dodge H, et al. Factors associated with resistance to dementia despite high Alzheimer disease pathology. Neurology 2009;72:354-360.
- 25. Barkhof F, Polvikoski TM, Van Straaten ECW, et al. The significance of medial temporal lobe atrophy. Neurology 2007;69:1521-1527.
- 26. Jack CR, Jr., Dickson DW, Parisi JE, et al. Antemortem MRI findings correlate with hippocampal neuropathology in typical aging and dementia. Neurology 2002;58:750-757.
- 27. Schwarz CG, Gunter JL, Wiste HJ, et al. A large-scale comparison of cortical thickness and volume methods for measuring Alzheimer's disease severity. Neuroimage Clin 2016;11:802-812.
- 28. Ball MJ, Fisman M, Hachinski V, et al. A new definition of Alzheimer's disease: a hippocampal dementia. Lancet 1985;1:14-16.
- 29. Yu L, Boyle PA, Dawe RJ, Bennett DA, Arfanakis K, Schneider JA. Contribution of TDP and hippocampal sclerosis to hippocampal volume loss in older-old persons. Neurology 2020;94:e142-e152.
- 30. Dawe RJ, Yu L, Arfanakis K, Schneider JA, Bennett DA, Boyle PA. Late-life cognitive decline is associated with hippocampal volume, above and beyond its associations with traditional neuropathologic indices. Alzheimers Dement 2020;16:209-218.
- 31. Zarow C, Wang L, Chui HC, Weiner MW, Csernansky JG. MRI shows more severe hippocampal atrophy and shape deformation in hippocampal sclerosis than in Alzheimer's disease. Int J Alzheimers Dis 2011;2011:483972.
- 32. Jagust WJ, Zheng L, Harvey DJ, et al. Neuropathological basis of magnetic resonance images in aging and dementia. Ann Neurol 2008;63:72-80.
- 33. Woodworth DC, Nguyen HL, Khan Z, Kawas CH, Corrada MM, Sajjadi SA. Utility of MRI in the identification of hippocampal sclerosis of aging. Alzheimer's & Dementia.
- 34. Kotrotsou A, Bennett DA, Schneider JA, et al. Ex vivo MR volumetry of human brain hemispheres. Magn Reson Med 2014;71:364-374.

35. Bejanin A, Murray ME, Martin P, et al. Antemortem volume loss mirrors TDP-43 staging in older adults with non-frontotemporal lobar degeneration. Brain 2019;142:3621-3635.